Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Archive of Views

<< 2013 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2015 >>

13 October 2014: London is a scientific powerhouse – and it’s about more than Nobel Prizes

By Stephen Caddick, Vice-Provost (Enterprise) at UCL
THE AWARD of the Nobel Prize in Physiology or Medicine this week to London-based professor John O’Keefe, along with his colleagues Moser and Moser, is well-deserved recognition for truly ground-breaking science – science which, in time, could have profound ramifications for the way we understand and treat neurological diseases like Alzheimer’s.
More...

<< 2013 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2015 >>